Hematologic Oncology

Expert discusses the emergence of recently approved bispecific antibodies in R/R LBCL, emphasizing the importance of toxicity management for adverse events such as cytokine release syndrome (CRS).

Insight into monitoring patients who are being treated for AML, what constitutes complete remission, and how and why it’s important to test for minimal residual disease to determine a patient’s risk for relapse.

Catherine E. Lai, MD, MPH, discusses the current standard of care in the first-line treatment of patients with AML and which factors guide therapy selection.

Expert perspectives on the role of biomarker testing in the diagnosis and management of acute myeloid leukemia.

Elizabeth Budde, MD, PhD, presents data from the 3-year follow-up from a pivotal phase II study investigating mosunetuzumab monotherapy in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies.

Panelist introductions by Gregory Roloff, MD from the University of Chicago Comprehensive Cancer Center, Chicago, Illinois; Jae Park, MD, Memorial Sloan Kettering Cancer Center, New York, New York; and Bijal Shah, MD, from the Moffitt Cancer Center, Tampa, Florida.

Elizabeth Budde, MD, PhD, presents data from on mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma.

Nicole Lamanna, MD, discusses the results from the ongoing BGB-11417-101 study investigating combination zanubrutinib plus sonrotoclax in patients with treatment-naïve CLL/SLL.

A hematologist/oncologist previews updated data presented at ASH 2023 for patients with B-cell malignancies.

Nicole Lamanna, MD, gives an overview of targeted therapies and the role of prognostic markers in the treatment of B-cell malignancies.

Claire Roddie, MD, PhD, presents data from the pooled analysis of the ongoing FELIX phase Ib/II study investigating obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.

Guillermo Garcia-Manero, MD, presents data from the COMMANDS trial investigating luspatercept in erythropoiesis-stimulating agent-naive patients with transfusion-dependent lower-risk myelodysplastic syndromes.

Key opinion leaders on diffuse large B-cell lymphoma management provide a review first-line treatment options.

Raajit K. Rampal, MD, PhD, presents data from the MANIFEST-2 study investigating pelabresib in combination with ruxolitinib in Janus kinase inhibitor treatment–naïve patients with myelofibrosis.

Experts explain how polycythemia vera is diagnosed and the typical symptoms a patient may present with.

Sergio Giralt, MD, provides a look at an upcoming OncLive Insights program in which he will offer insights on the evolving treatment landscape for patients with veno-occlusive disease.

A comprehensive overview of clinical and patient factors that impact disease progression beyond CAR T-cell therapy in lymphoma.

Gain insights into treatment outcomes of CAR T, highlighting lisocabtagene maraleucel and the TRANSCEND NHL 001 study for R/R LBCL.

Experts on follicular lymphoma discuss first-line treatment options available for patients.

Experts discuss what role allogeneic transplants play in hematologic malignancies, specifically in AML and ALL.

Join Catherine Lai, MD, MPH in this informative OncLive News Network program as she explores strategies for optimizing outcomes in the long-term management of Acute Myeloid Leukemia (AML), with a focus on patients in first remission without a transplant. Here, she provides a brief overview of the current incidence of AML, its risk factors, and prognosis.

Akshat Jain, MBBS, discusses the importance of novel therapies in the treatment of pediatric patients with beleeding disorders.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Treatment with asciminib elicited greater efficacy and had a more tolerable safety profile compared with bosutinib for patients chronic myeloid leukemia in chronic phase following treatment with 2 or more TKIs.

Following promising preclincial findings, acimtamig plus allogenic natural killer cells will be examined for the treatment of patients with relapsed/refractory Hodgkin lymphoma and CD30-positive peripheral T-cell lymphoma.